Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4…
Metabolic Disorders
-
-
Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes
Novo Nordisk is advancing its amylin agonist, amycretin, to Phase III in type 2 diabetes (T2D) after the drug met…
-
Innovent boasts another pivotal trial success for obesity drug
Innovent Biologics’ obesity drug has shown success in another pivotal trial, meeting the primary and all key secondary endpoints. In…
-
Eledon’s transplant rejection drug shows promise in Phase I/II diabetes trial
Eledon Pharmaceuticals’ drug to prevent islet transplantation rejection in type 1 diabetes has led to an insulin-free life in patients…
-
Lilly to advance alternative obesity candidate to Phase III
Eli Lilly is advancing its obesity treatment candidate, which is an alternative to glucagon-like peptide-1 receptor agonists (GLP-1RAs), to Phase…
-
Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity
Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by…
-
Wave Life Sciences’ obesity siRNA shows “once or twice-yearly” potential
Wave Life Sciences’ siRNA obesity drug has shown promise in various biomarkers in an early-stage trial. In the Phase I…
-
Eli Lilly’s oral GLP-1RA gains fourth Phase III type 2 diabetes win
Eli Lilly’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has shown success again in two more Phase III trials in patients…
-
Pfizer’s obesity bet shows 14.1% weight loss in Phase IIb trial
Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight loss reported in a Phase IIb trial.…
-
Lilly’s orforglipron trumps oral semaglutide in head-to-head trial
Eli Lilly appears to have regained the lead over Novo Nordisk in the oral cardiometabolic treatment arena, following results from…
